8-K current report · filed Aug 5, 2026

Protagonist Therapeutics, Inc (PTGX) 8-K Current Report: August 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2PTGX overview

Short answer

Protagonist Therapeutics, Inc (PTGX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 results reported for quarter ended June 30, 2026.

Protagonist Therapeutics, Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results reported for quarter ended June 30, 2026
  • Corporate update accompanies earnings release in Exhibit 99.1
  • Investors should review Exhibit 99.1 for financial metrics and pipeline developments

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation furnished August 5, 2026 under Regulation FD
  • Investor-relevant information resides in Exhibit 99.2, potentially covering pipeline and corporate developments

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $213.5M, primarily $192.4M Takeda opt-out recognition; reported net income $162.8M versus $34.8M loss
  • Cash, equivalents and marketable securities $849.5M, up from $646.0M at December 31, 2025
  • Rusfertide NDA under FDA Priority Review with August 2026 PDUFA date; approval could trigger $75M milestone plus royalties up to 29%
  • ICOTYDE’s first full commercial quarter supports royalty-based upside, with 6%-10% global sales royalties and up to $580M additional milestones
  • R&D expected to increase significantly in second half 2026 as PN-881 advances toward Phase 2 and obesity programs progress

Item EX-99.2 · Exhibit EX-99.2

  • Presentation highlights $912.5M earned partnership payments through June 2026, supporting internally funded pipeline development
  • ICOTYDE FDA approved in March 2026, with 6% to 10% royalties and $580M future milestones from J&J
  • Rusfertide FDA decision targeted August 2026, with 14% to 29% royalties and $1.05B future milestones from Takeda
  • Company reports $849.5M cash in Q2 2026 and no expected equity raise in the foreseeable future
  • Pipeline value inflections include PN-881 Phase 2b psoriasis initiation in early Q1 2027 and PN-8047 Phase 1 initiation in Q1 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Protagonist Therapeutics, Inc 8-K filings

Get the next PTGX 8-K as it lands

Follow PTGX for push alerts, or ask the research agent what this filing means.